Oxidative damage is widespread in the brain in Alzheimer's Disease (AD) and may be related to amyloid-beta (Abeta) toxicity. Clinical and epidemiological evidence suggests that antioxidants such as vitamin E and vitamin C may lower the risk of AD or delay clinical milestones. Indole-3-propionic acid (IPA) is a highly potent, naturally occurring antioxidant that also inhibits fibril formation by Abeta. The objectives of this proposal are to conduct a phase IB study of IPA in patients with AD to assess its safety and tolerability. In addition, levels of biological markers related to oxidative damage and to AD will be measured, to assess central and peripheral biological activity of IPA. A 12 week, double blind, placebo-controlled multi-center study will be conducted. Patients will be assigned in a 4:1 ratio to receive IPA (40 patients total) or an identical placebo (10 patients) and will receive treatment for 12 weeks. Treatment during the first 4 weeks will be a low dose, followed by 4 weeks of a medium dose and 4 weeks of a higher dose. The primary outcome measure will be safety, assessed by frequencies of clinical and biochemical adverse events. Secondary outcome measures will be changes in levels of biological markers in plasma (8,12-isoprostane-F2) and cerebrospinal fluid (8,1-isoprostane-F2, tau and Abeta42) from baseline to 12 weeks. Pharmacokinetic information will be assessed using measures of plasma and CSF levels of IPA in relation to doses of IPA. Pharmacokinetic information will be assessed using measures of plasma and CSF levels of IPA in relation to doses of IPA. Clinical measures of cognition (ADAScog) and function (ADCS-ADL) will be used as further assessments of safety or of possible beneficial short-term effects on AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG010483-12
Application #
6653993
Study Section
Special Emphasis Panel (ZAG1)
Project Start
2002-09-01
Project End
2003-06-30
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications